Elevated Serum Ceruloplasmin Levels Are Associated with Higher Impulsivity in People with Parkinson's Disease.
Journal
Parkinson's disease
ISSN: 2090-8083
Titre abrégé: Parkinsons Dis
Pays: United States
ID NLM: 101539877
Informations de publication
Date de publication:
2020
2020
Historique:
received:
28
05
2020
revised:
21
08
2020
accepted:
19
09
2020
entrez:
16
10
2020
pubmed:
17
10
2020
medline:
17
10
2020
Statut:
epublish
Résumé
Heightened impulsivity has been reported in a subset of people with Parkinson's disease (PwP) and is considered a risk factor for the development of impulse control disorders (ICDs). However, at present, there are no recognised biochemical markers of heightened impulsivity. To determine if ceruloplasmin, a serum marker involved in the regulation of iron and copper homeostasis, is associated with trait impulsivity in PwP. The study measured serum ceruloplasmin and impulsivity using the Barratt Impulsiveness Scale (BIS-11) in an Australian cohort of 214 PwP. Multivariate general linear models (GLMs) were used to identify whether higher serum ceruloplasmin levels (>75th percentile) were significantly predictive of BIS-11 scores. Serum ceruloplasmin was higher in females with PD ( Higher serum ceruloplasmin levels are independently associated with heightened nonplanning impulsivity in PwP. Thus, serum ceruloplasmin levels may have clinical utility as a marker for heightened impulsivity in PD.
Sections du résumé
BACKGROUND
BACKGROUND
Heightened impulsivity has been reported in a subset of people with Parkinson's disease (PwP) and is considered a risk factor for the development of impulse control disorders (ICDs). However, at present, there are no recognised biochemical markers of heightened impulsivity.
OBJECTIVES
OBJECTIVE
To determine if ceruloplasmin, a serum marker involved in the regulation of iron and copper homeostasis, is associated with trait impulsivity in PwP.
METHODS
METHODS
The study measured serum ceruloplasmin and impulsivity using the Barratt Impulsiveness Scale (BIS-11) in an Australian cohort of 214 PwP. Multivariate general linear models (GLMs) were used to identify whether higher serum ceruloplasmin levels (>75th percentile) were significantly predictive of BIS-11 scores.
RESULTS
RESULTS
Serum ceruloplasmin was higher in females with PD (
CONCLUSIONS
CONCLUSIONS
Higher serum ceruloplasmin levels are independently associated with heightened nonplanning impulsivity in PwP. Thus, serum ceruloplasmin levels may have clinical utility as a marker for heightened impulsivity in PD.
Identifiants
pubmed: 33062249
doi: 10.1155/2020/8296203
pmc: PMC7545407
doi:
Types de publication
Journal Article
Langues
eng
Pagination
8296203Informations de copyright
Copyright © 2020 Megan C. Bakeberg et al.
Déclaration de conflit d'intérêts
The authors declare that there are no conflicts of interest regarding the publication of this paper.
Références
Exp Brain Res. 2011 Jul;212(3):371-84
pubmed: 21643718
J Biol Chem. 2003 Jul 18;278(29):27144-8
pubmed: 12743117
Ann Neurol. 2011 Jun;69(6):986-96
pubmed: 21416496
Mov Disord. 2011 Feb 15;26(3):464-8
pubmed: 21312278
Parkinsons Dis. 2019 Oct 1;2019:2672075
pubmed: 31662842
J Card Fail. 2014 Dec;20(12):946-52
pubmed: 25128745
Eur J Neurol. 2009 Oct;16(10):1130-7
pubmed: 19572946
Neurochem Res. 2011 Nov;36(11):2111-5
pubmed: 21706376
Parkinsonism Relat Disord. 2013 Jul;19(7):698-700
pubmed: 23611687
Synapse. 2005 Nov;58(2):122-8
pubmed: 16088951
Cogn Neuropsychiatry. 2007 May;12(3):213-21
pubmed: 17453902
Brain. 2014 Jul;137(Pt 7):1986-97
pubmed: 24893708
Neuropsychiatr Dis Treat. 2006 Dec;2(4):577-81
pubmed: 19412506
Psychiatry Res. 2012 Apr 30;202(1):60-4
pubmed: 22595510
J Behav Addict. 2015 Dec;4(4):263-72
pubmed: 26690621
Brain. 2011 Jan;134(Pt 1):50-8
pubmed: 21109502
J Exp Psychol Gen. 1999 Mar;128(1):78-87
pubmed: 10100392
Am J Physiol. 1991 Feb;260(2 Pt 1):L68-74
pubmed: 1996664
Int J Psychiatry Clin Pract. 2014 Aug;18(3):156-60
pubmed: 24151922
Parkinsons Dis. 2018 Apr 19;2018:9472120
pubmed: 29850017
Ann Indian Acad Neurol. 2015 Jul-Sep;18(3):366
pubmed: 26425030
Ther Adv Neurol Disord. 2013 May;6(3):175-88
pubmed: 23634190
Neuron. 2011 Feb 24;69(4):680-94
pubmed: 21338879
Int J Geriatr Psychiatry. 2006 Nov;21(11):1078-85
pubmed: 16977673
Arch Neurol. 2007 Feb;64(2):212-6
pubmed: 17296836
Brain Behav. 2018 Jun;8(6):e00995
pubmed: 29733522
Indian J Psychiatry. 2011 Apr;53(2):170-1
pubmed: 21772656
J Neurol Neurosurg Psychiatry. 2004 Apr;75(4):539-44
pubmed: 15026491
Schizophr Res. 2006 Sep;86(1-3):167-71
pubmed: 16842975
Mov Disord. 2007 Jan;22(1):41-7
pubmed: 17115387
J Biol Chem. 1988 May 5;263(13):6281-7
pubmed: 3360784
J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4
pubmed: 1564476
Front Neurol. 2019 Apr 17;10:351
pubmed: 31057473
Acta Psychiatr Scand. 2007 Jan;115(1):41-7
pubmed: 17201865
Free Radic Biol Med. 2008 Feb 1;44(3):483-92
pubmed: 17991445
Pharmacol Toxicol. 1999 Nov;85(5):239-43
pubmed: 10608487
Front Neurosci. 2019 Aug 07;13:839
pubmed: 31440136
Mov Disord. 2008 Feb 15;23(3):411-5
pubmed: 18067187
Psychiatry Res. 2011 May 15;187(1-2):301-3
pubmed: 21106252
Oxid Med Cell Longev. 2014;2014:147251
pubmed: 24672633
Behav Brain Funct. 2008 Nov 18;4:52
pubmed: 19017404
Neurology. 2005 Nov 22;65(10):1570-4
pubmed: 16301483
NPJ Parkinsons Dis. 2017 Jan 11;3:3
pubmed: 28649603
Arch Neurol. 2010 May;67(5):589-95
pubmed: 20457959